CHEK2 1100delc: Cancer Risks and Medical Management

The CHEK2 c.1100delC variant is a moderate-penetrance genetic change that roughly doubles or triples a woman’s risk of breast cancer compared to the general population, and it raises the odds of several other cancers as well. Found in roughly one percent of people of European descent, this single deletion in the CHEK2 gene knocks out the function of a protein that normally helps cells repair damaged DNA. Because it sits in a middle ground between high-risk genes and ordinary background risk, 1100delC creates a set of medical management questions that don’t have the same straightforward answers as, say, a BRCA1 mutation.

What the Variant Actually Does

CHEK2 encodes a protein called CHK2, which acts as a checkpoint kinase in the cell’s DNA damage response. When a cell’s DNA sustains a double-strand break, CHK2 helps coordinate the repair process, working alongside better-known proteins like BRCA1 and p53. The 1100delC variant is a frameshift deletion that truncates the protein and eliminates its kinase activity, effectively leaving cells without this particular layer of quality control.

Without functional CHK2, cells are worse at repairing the kind of serious DNA damage that can lead to uncontrolled growth. The original landmark study that brought this variant into the spotlight found it in about 1.1% of healthy individuals but in 5.1% of breast cancer patients from families without BRCA1 or BRCA2 mutations, establishing it as a bona fide cancer susceptibility variant.

Breast Cancer Risk in Women

A large collaborative analysis involving more than 10,000 breast cancer cases and 9,000 controls found that carrying one copy of 1100delC was associated with an odds ratio of about 2.3 for breast cancer. The variant turned up in roughly 1.9% of cases versus 0.7% of controls. There was also a suggestion that risk was somewhat higher in women diagnosed at younger ages and in those with a first-degree relative who had breast cancer.¹ A recent narrative review of the broader CHEK2 literature puts the breast cancer risk increase from pathogenic CHEK2 variants at roughly two- to threefold, consistent with the variant’s classification as a moderate-penetrance gene.²

That two- to threefold figure is population-level. For an individual woman, what that translates to in terms of absolute lifetime risk depends heavily on other factors, including family history and background genetic risk, which we’ll get to shortly.

Contralateral Breast Cancer

One of the more clinically actionable risks for women who have already been diagnosed with breast cancer on one side is the chance of developing a second cancer in the other breast. For CHEK2 carriers, this risk is meaningfully elevated compared to non-carriers, though not as high as for BRCA1 or BRCA2 carriers. In a study tracking contralateral breast cancer rates, premenopausal CHEK2 carriers had an estimated 10-year risk of about 13%, while postmenopausal carriers had about a 4% risk over the same period.³ For context, those same figures were roughly 33% and 12% for BRCA1 carriers, so the CHEK2 contralateral risk is real but clearly lower.

The elevated contralateral risk also appears to carry consequences for survival. Research has shown that breast cancer patients with the 1100delC variant have worse breast cancer-specific survival compared to non-carriers, a finding at least partly attributable to the added burden of second primaries.⁴

What 1100delC Tumors Tend to Look Like

Breast cancers in 1100delC carriers have a fairly consistent molecular profile. They are overwhelmingly estrogen receptor (ER) positive. One study found that about 95% of tumors in carriers were hormone receptor positive, compared to roughly 81% in non-carriers.⁵ Another study focused on early-onset symptomatic breast cancer confirmed that CHEK2-associated tumors were significantly more likely to be ER- and progesterone receptor-positive and to be grade 2 rather than grade 3.⁶

On the surface, ER-positive, moderate-grade tumors sound like they should carry a better prognosis, and in most settings they do. But here’s an important nuance: despite the favorable tumor profile, CHEK2 carriers with early-onset breast cancer can still face an adverse prognosis, likely because of the elevated contralateral risk and the possibility of additional primary tumors. A separate study of ER-positive tumors found that carriers were more often diagnosed with small tumors but also more frequently had lymph node involvement.⁷ The takeaway is that looking at grade and receptor status alone can be misleading when the underlying genetics push toward multiple cancers over a lifetime.

Cancer Risks Beyond the Breast

Breast cancer dominates the research on 1100delC, but it isn’t the only site affected. Several other tumor types show meaningful associations with this variant, though the evidence varies in strength.

Male breast cancer: The original CHEK2 landmark paper estimated an approximately tenfold increase in breast cancer risk for male carriers.⁸ A Dutch study confirmed this, finding the 1100delC variant in about 4.2% of unselected male breast cancer cases compared to 1.1% population frequency, yielding an odds ratio of roughly 4.⁹ Male breast cancer is rare to begin with, so even a substantial relative increase translates to a modest absolute risk, but it is enough that male relatives of female carriers warrant awareness.
Prostate cancer: A meta-analysis pooling data across multiple studies found that 1100delC carriers had roughly double the risk of prostate cancer overall, with a higher odds ratio of about 3.4 for familial cases.¹⁰
Colorectal cancer: The picture here is muddier. A meta-analysis of six studies including about 4,200 cases and 10,000 controls found a significant association between 1100delC and unselected colorectal cancer, with an odds ratio of about 2.1, and a stronger association for familial cases. However, no clear link emerged for sporadic colorectal cancer.¹¹ Individual studies from different countries have produced conflicting results, with Finnish data showing no excess and Dutch data showing a trend that didn’t reach statistical significance.¹²
Other sites: Associations with kidney cancer, thyroid cancer, and blood cancers have been reported in the literature, though these are based on fewer studies and often on CHEK2 variants collectively rather than 1100delC specifically.²

One important point about 1100delC and ovarian cancer: unlike BRCA1 and BRCA2, CHEK2 pathogenic variants do not appear to raise ovarian cancer risk. This distinction matters because it affects which risk-reducing surgeries are appropriate.¹³

How Background Genetics Modify the Risk

One of the most important developments in understanding 1100delC in recent years is the recognition that your background genetic profile meaningfully shifts where you fall on the risk spectrum. Researchers have shown that a polygenic risk score, a composite measure of many common genetic variants across the genome, modifies breast cancer risk for CHEK2 carriers in the same multiplicative way it does for non-carriers.¹⁴

What this means in practice is striking. Carriers in the highest quintile of the polygenic risk score had an odds ratio of roughly 2.0 on top of their CHEK2 risk, which would push their total lifetime breast cancer risk into what U.K. guidelines classify as “high risk.” Carriers in the lowest quintile, on the other hand, had an odds ratio of about 0.5, which brought their overall risk back down near the population average. So two women can both carry the exact same 1100delC variant but have very different actual breast cancer risks depending on the rest of their genomes.

Comprehensive risk models that incorporate CHEK2 carrier status, polygenic risk scores, and individual clinical factors like family history and breast density are being developed to provide more personalized risk estimates.¹⁵ These tools aren’t yet universally available in clinical practice, but they represent a shift away from treating all CHEK2 carriers the same.

Homozygous Carriers Face a Much Higher Risk

Most of the risk figures discussed so far apply to heterozygous carriers, meaning people with one altered copy and one normal copy of CHEK2. Homozygous carriers, those with two copies of 1100delC, are rare but face dramatically higher risks. A Dutch study of familial breast cancer cases identified eight homozygous women and found their breast cancer risk was more than double that of heterozygous carriers from the same population. Seven out of ten homozygous women in the study developed multiple primary tumors.¹⁶

Because 1100delC is present in roughly 1% of people with Northern European ancestry, homozygosity would be expected in roughly 1 in 10,000 individuals. That’s rare enough that most clinicians will never encounter it, but when it does come up on genetic testing, the management implications are quite different from those for a heterozygous carrier.

Screening and Surveillance Recommendations

For women who carry 1100delC and haven’t been diagnosed with breast cancer, enhanced breast surveillance is the standard recommendation. This typically means the addition of breast MRI to standard mammography, reflecting the variant’s classification as a moderate-risk finding that warrants more than population-level screening. A comparative modeling analysis of different screening strategies for women with CHEK2 pathogenic variants supported the use of both mammography and MRI.¹⁷

For colorectal cancer screening, expert panels have recommended colonoscopy every five years starting at age 40 for CHEK2 carriers, though it’s worth noting that the specific association between 1100delC and colon cancer remains debated. For prostate cancer, formal guidelines from major organizations have been slow to incorporate CHEK2-specific recommendations, but clinician panels have suggested annual PSA testing starting at age 40 for male carriers, particularly those with relevant family history.¹⁸

What is explicitly not recommended, but sometimes done anyway, is risk-reducing salpingo-oophorectomy (removal of the ovaries and fallopian tubes). Because CHEK2 does not increase ovarian cancer risk, this surgery offers no cancer-prevention benefit for carriers and exposes them to unnecessary surgical menopause.

Surgical Decisions After a Breast Cancer Diagnosis

When a CHEK2 1100delC carrier is diagnosed with breast cancer, the question of how aggressively to approach surgery becomes more complicated than for an average patient. The elevated contralateral risk, especially in younger women, tilts the conversation toward more extensive surgery. Research on surgical decision-making in CHEK2 and PALB2 carriers has shown that patients who learn of their mutation status tend to choose more definitive surgical approaches. Those who knew their status at the time of initial treatment opted for mastectomy more often, while those who learned only later had a high rate of conversion from breast-conserving therapy to mastectomy, often after recurrence.¹⁹

That said, mastectomy is not automatically the right answer for every CHEK2 carrier with breast cancer. For postmenopausal women with a 10-year contralateral risk of roughly 4%, the absolute benefit of removing the other breast is modest. For premenopausal women facing a 13% 10-year risk, the calculus looks different, and the conversation about contralateral prophylactic mastectomy becomes more relevant. The point is that these discussions should happen early, ideally before the initial surgery, so that a carrier has full information about recurrence and contralateral risk when making treatment decisions.

Chemoprevention With Tamoxifen

Because 1100delC-associated breast cancers are overwhelmingly ER-positive, hormonal chemoprevention is a potentially useful strategy. Tamoxifen, which blocks estrogen signaling in breast tissue, has long been used to reduce breast cancer risk in high-risk women, and there is a pharmacological rationale for it working well in CHEK2 carriers specifically. Greek researchers studying CHEK2 carrier families have emphasized the possible role of tamoxifen as a risk-reducing option, especially given the tendency for some carriers and their physicians to pursue more aggressive surgical measures than the moderate-risk classification warrants.¹³

Tamoxifen isn’t without side effects, including hot flashes, blood clot risk, and endometrial effects, so it’s not a universal recommendation. But for carriers who want an alternative to enhanced surveillance alone, particularly those whose polygenic risk score places them at the higher end of the spectrum, chemoprevention is a conversation worth having.

Cascade Testing in Families

When one person in a family is found to carry 1100delC, first-degree relatives each have a 50% chance of carrying the same variant. Cascade testing, where you offer targeted genetic testing to close relatives, is a straightforward and cost-effective way to identify additional carriers who might benefit from earlier or enhanced screening. In practice, uptake is variable. In one Greek cohort, nearly half of families responded to cascade testing offers, which is a reasonable rate but still means half of the families with a known mutation in circulation didn’t participate.

The challenge with cascade testing for a moderate-risk variant is that the medical payoff per person identified is smaller than for BRCA1 or BRCA2 testing. A newly identified 1100delC carrier gets added breast screening with MRI and possibly colonoscopy starting at 40, but they are not facing the kind of high-penetrance risk that might prompt prophylactic surgery. For some family members, the psychological cost of carrying a “cancer gene” label may outweigh the practical benefit of knowing, especially if their polygenic background puts them at the lower end of the risk spectrum. Genetic counseling that frames 1100delC honestly, as a moderate risk modifier rather than a cancer sentence, helps set realistic expectations.

Emerging Research on Immunotherapy Response

An intriguing new thread in CHEK2 research focuses on how loss of CHK2 function affects the immune system’s ability to recognize and attack tumors. When CHEK2 is non-functional, the impaired DNA repair can lead to an accumulation of DNA damage in tumor cells, which in turn appears to recruit CD8+ cytotoxic T-cells, the immune cells responsible for killing abnormal cells. Early research suggests this could make tumors in CHEK2-deficient patients more responsive to immune checkpoint inhibitor therapy.²⁰

This area is still largely preclinical and speculative, so no treatment decisions should be made on it today. But it raises an interesting possibility: the same DNA repair deficiency that increases cancer risk might also make those cancers more vulnerable to a specific class of treatment. If this pans out, CHEK2 carrier status could eventually influence not just screening and prevention strategies but also treatment selection after a cancer diagnosis.

1
American Journal of Human Genetics. CHEK2*1100delC and susceptibility to breast cancer: a collaborative analysis involving 10,860 breast cancer cases and 9,065 controls from 10 studies
2
PubMed Central. CHEK2 variants, breast cancer, and implications for management: a narrative review
3
PubMed Central. Contralateral Breast Cancer Risk Among Carriers of Germline Pathogenic Variants in ATM, BRCA1, BRCA2, CHEK2, and PALB2
4
PubMed. Association of the CHEK2 c.1100delC variant, radiotherapy, and systemic treatment with contralateral breast cancer risk and breast cancer-specific survival
5
British Journal of Cancer. Survival and contralateral breast cancer in CHEK2 1100delC breast cancer patients: impact of adjuvant chemotherapy
6
PubMed Central. Pathogenic Variants in CHEK2 Are Associated With an Adverse Prognosis in Symptomatic Early-Onset Breast Cancer
7
The Breast. Outcomes for ER-positive CHEK2 c.1100delC breast cancer patients compared with breast cancer patients without the variant
8
PubMed. Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutations
9
PubMed. CHEK2 1100delC and male breast cancer in the Netherlands
10
PubMed Central. CHEK2 (*) 1100delC Mutation and Risk of Prostate Cancer
11
PubMed. Meta-analysis of CHEK2 1100delC variant and colorectal cancer susceptibility
12
European Journal of Human Genetics. Germline CHEK2 mutations and colorectal cancer risk: different effects of a missense and truncating mutations?
13
PubMed Central. CHEK2 Pathogenic Variants in Greek Breast Cancer Patients: Evidence for Strong Associations with Estrogen Receptor Positivity, Overuse of Risk-Reducing Procedures and Population Founder Effects
14
PubMed. Genetic modifiers of CHEK2*1100delC-associated breast cancer risk
15
PubMed Central. Comprehensive Breast Cancer Risk Assessment for CHEK2 and ATM Pathogenic Variant Carriers Incorporating a Polygenic Risk Score and the Tyrer-Cuzick Model
16
PubMed. CHEK2*1100delC homozygosity is associated with a high breast cancer risk in women
17
PubMed Central. Breast Cancer Screening Strategies for Women With ATM, CHEK2, and PALB2 Pathogenic Variants: A Comparative Modeling Analysis
18
PubMed Central. Clinical Interpretation of Pathogenic ATM and CHEK2 Variants on Multigene Panel Tests: Navigating Moderate Risk
19
Archives of Breast Cancer. Surgical Decision Making and Management of CHEK2 and PALB2 Breast Cancer Mutation Carriers
20
Oncotarget. Beyond DNA damage response: Immunomodulatory attributes of CHEK2 in solid tumors